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Reply
We appreciate the comments from Drs. Bode and Simpson
regarding our report on simvastatin’s effect on skeletal muscle.
We agree that a crossover design would be a more optimal
approach. However, we did find that the case patients and control
individuals were appropriately and close to optimally matched
when the present design was applied.
The inherent “clinical” differences between case and control indi-
viduals as Drs. Bode and Simpson suggested are possible but in our
minds unlikely. In support for their contention, they cited a paper for
finding alterations in coenzyme Q10 concentrations in patients with
diabetes, but unfortunately the essential information of whether these
patients were being treated with statins is lacking (1).
We do not claim to have proven that a decrease in coenzyme
10 content is instrumental in the myalgia. Rather, we wrote that
he impaired oxidative phosphorylation capacity was a plausible
echanistic explanation for the muscle pain.
A study conducted in mice showed that treatment with a
ipophilic statin (atorvastatin) impaired mitochondrial activity
NADH oxidase activity) as well as ubiquinone content without an
ffect on mitochondrial density, compared with control mice (2).
This was reversed with coenzyme Q10 supplementation (2). This
tudy confirmed that the statin treatment itself had the negative
ffect on skeletal muscle (2), as we reported in our study (3).
owever, overall reports on the effects of coenzyme Q10 supple-
entation on myalgia are ambiguous (4,5), but none of these
tudies investigated coenzyme Q10 content in human skeletal
uscle.
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Issues Needing Clarification
Regarding Population
Characteristics in the Analysis
From the National Cardiovascular
Data Registry
We read with interest the paper by Baklanov et al. (1), but we
think that some issues need to be clarified regarding the population
characteristics of the Prevalence and Outcomes of Transradial
Percutaneous Coronary Intervention for ST-Segment Elevation
Myocardial Infarction: Analysis From the National Cardiovascular
Data Registry (2007 to 2011).
First, there is no information about sheath sizes used in the
study groups. One of the endpoints was bleeding, and overt
access site bleeding and retroperitoneal hemorrhage within 72 h
of percutaneous coronary intervention (PCI) were included in
the definition of bleeding. Doyle et al. (2) reported that using
sheath sizes 6-F was identified as a strong independent
predictor of major femoral bleeding. Trimarchi et al. (3)
eported that adopting a sheath size of 8-F or larger was
ndependently related to independent predictors of retroperito-
eal hematoma after PCI.
Second, the incidence of high-risk C-type coronary lesions was
ignificantly greater in the femoral access group compared with the
adial access group. Barbash et al. (4) concluded that a type-C
oronary lesion was an angiographic predictor of PCI failure for
T-segment elevation myocardial infarction. In addition, Wilen-
ky et al. (5) reported that PCI for complex lesions was associated
ith increased in-hospital mortality. When considering that PCI
uccess and mortality were defined as primary endpoints of the
tudy, results may be affected because of this difference between
roups.
